Souhaitez-vous accéder aux communiqués récents ?

Pluri entered strategic collaborations across Asia, Europe and the United States (“U.S.”) to transform food and agriculture production via its subsidiaries’ advanced cell expansion...

State-backed collaboration outlines a multi-phase, capital-light path from cell line development to pilot-scale biofarming and evaluation of commercial-scale manufacturing in ChiapasCoffeesai...

Major milestones include entry into cultivated cacao and coffee markets and progress toward commercial-scale productionCompany reports nearly 400% revenue growth in the first nine months of fiscal...

Acquisition of approximately 71% stake in Kokomodo Ltd.Acquisition uniquely combines Pluri's mass-scale cell production expertise with Kokomodo Ltd.’s ability to craft real, controlled,...

Latest granted patents reinforce Pluri’s position as a leader in Mucosal-Associated Invariant T (“MAIT”) cell-based cell therapies for solid cancersPluri’s MAIT platform enables commercial scale...

Strategic initiative to address Ukraine’s urgent need for radiation countermeasures Hemafund's infrastructure ensures secure storage and rapid deployment of emergency treatments Collaboration may...

New investment follows recent private placement of $6.5 million with global investor and entrepreneur, Mr. Alejandro WeinsteinFunds are intended to support Pluri’s growth and execution strategy as a...

Private placement of $6.5 million with a global investor and entrepreneur, Mr. Alejandro Weinstein, who will join Pluri’s Board of DirectorsPluri to purchase approximately 71% of Kokomodo Ltd.’s...

HAIFA, Israel, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) ("Pluri" or the “Company"), an innovator in the development of leading cell-based technologies for various...

HAIFA, Israel, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE:PLUR) ("Pluri" or the “Company"), a leading biotechnology company leveraging its proprietary platform for cell-based...